All News

Can IL-22 differentiate between IL-17 & TNF inhibitor #PSA responders? Pilot study 2 cohorts 81 PSA pts showed both biologics worked but somewhat better response in IL-17i Pts w/ low IL- & TNFi responses w/ high IL-22 levels. https://t.co/txyNl2OwTP

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast square

Male vs. Female Responders (4.15.2022)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal Reports from the past week on RheumNow.com - including fellowship COVID-19 concerns, the limits of T2T in gout and the real odds of RA remission with your first biologic. 

Read Article
NPF COVID-19 report from AAD mtg shows #PSA pts on systemic Rx were not at risk of hospitalization or severe COVID-1 based on US claims data. Also TNFi, IL-17, IL-23 Rx not affect on Vax Ab responses; less hosp (36%) w/ TNFi https://t.co/ekvu0mMvrn https://t.co/Qogm1Vx5hF

Links:

Dr. John Cush RheumNow ( View Tweet)
dementia,brain

Is Alzheimer's Risk Lower With TNF Inhibitors?

d MedPage Today

Tumor necrosis factor (TNF) inhibitors for rheumatoid arthritis were linked with a lower risk of Alzheimer's disease and related dementia, but only in people with cardiovascular disease, data from the DREAM (Drug Repurposing for Effective Alzheimer's Medicines) study showed.

Read Article
2020 Pt preferences survey- 137 #PsA pts most took TNFi (30%), IL-17i (20%), MTX (10%). From 2018 to 2020 a signif incr in IL-17i & PDE4 inhib. Pts want Rx for damage (80%), ADL (71%), & pain (70%) https://t.co/2dyIuQubh5 https://t.co/sFbtRj0Lbv

Links:

Dr. John Cush RheumNow ( View Tweet)
Useful TST (PPD)/IGRA interpreter website for TB testing. A 31 yoM Texan w/ +IGRA only (true pos) has risk of active TB & INH hepatitis 0.1% & 0.4%. But if this was 60 yoF from Iraq on TNFi & pred the same risks are 20% & 2.3% https://t.co/M18cHuLrXu https://t.co/zIoFY4abXN

Links:

Dr. John Cush RheumNow ( View Tweet)
Czech registry compared drug survival csDMARDs vs TNFi monotherapy. Drug retention higher w/ combo (47 vs 23 mos; p < 0.001) than TNFi monotherapy. 5 yr survival was better 45% vs 26%; Combo w/ MTX > other csDMARDs (p = 0.003). https://t.co/pjbXwEQ53K https://t.co/nZj64Wk3Pt

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 1899 ankylosing spondylitis pts(10 RCTs) shows TNFi resp can be predicted - 34% had major resp vs 34% w/ no resp @ wk12. A major resp increased w/ higher CRP, Pt Global & BASDAI-Q2 score & decr w/ higher BMI & BASFI https://t.co/DrT7EVcZi0 https://t.co/CcFicTM0Mo

Links:

Dr. John Cush RheumNow ( View Tweet)
Psoriasis Severe legs sara

Differences in Biologic Persistence in Psoriasis and Psoriatic Arthritis

d Jack Cush, MD

Administrative claims analysis of biologic use in psoriasis (PsO) and psoriatic arthritis (PsA) in French health insurance databases shows that despite widespread biologic use, overall drug persistence (beyond 3 years) was low for PsO and PsA biologics.

Read Article
RheumNow Podcast square

Lupus Worries (3-25-22)

d Jack Cush, MD

Dr. Jack Cush Reviews the news and journal reports from the past week in RheumNow.com.

Read Article
Ask Cush Anything! Have a rheumatology question or case for Dr. Cush? Submit it here and we may feature it on an upcoming podcast. https://t.co/KgPIeScthr https://t.co/nk4re9mlcH

Links:

Dr. John Cush RheumNow ( View Tweet)
CV,risk,MI,heart,cardiac

Stable Low Risk of Acute Coronary Syndrome in RA

d Jack Cush, MD

A Nordic multinational collaborative study examined the risk of acute coronary syndrome (ACS) in rheumatoid arthritis and found a less than 2 fold increased risk of ACS patients initiating biologic disease-modifying antirheumatic drugs (bDMARDs) with little risk variation with short-ter

Read Article
PsA.Hands_.jpg

Adalimumab Addition vs. Methotrexate Escalation in Psoriatic Arthritis

d Jack Cush, MD

An interesting study in Lancet Rheumatology shows that psoriatic arthritis patients not responding to methotrexate alone can respond after adding or escalating adalimumab (ADA) on top of methotrexate (MTX) to reach minimal disease activity (MDA) response. 

Read Article
@Janetbirdope on drug cycling in #RA. What’s beyond TNFi failure? No golden rule, but: 👉🏻 switching to non-TNF can be superior than staying with the TNFi class 👉🏻 response to other bDMARs maybe blunted in non-TNFi naive 👉🏻 JAKi can be a good choice for some @RheumNow #RNL2022 https://t.co/25MiiFh2CK
Elena MyasoedovaMD MyasoedovaElena ( View Tweet)
@Janetbirdope on drug cycling vs. switching in RA Interesting data showing switching to non-TNFi superior to cycling in TNFi-incomplete responders Most bDMARDs and JAKi have blunted response post-TNFi @RheumNow #RNL2022 https://t.co/Lb3wvHZdzN
Robert B Chao, MD doctorRBC ( View Tweet)
Impact of fibromyalgia on Anti-TNF treatment response!! Philip Mease @RheumNow #Rnl2022 https://t.co/BYdZA3uu94
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
TNFi and pregnancy No association w/ congenital anomalies/infant infection Discontinuation of TNFi before wk 24, increases risk of disease flare Biologic lvls low in breast milk Does not affect vaccine response Live rotavirus vaccine did not cause infection @RheumNow #RNL2022 https://t.co/ZNdjf5qNDb
Robert B Chao, MD doctorRBC ( View Tweet)
Synergetic effect of IL17 and TNF in PSA. Bruce Kirkham @RheumNow #Rnl2022 https://t.co/acfqiluJWR
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
PSA management: MTX can be used alone TNF and MTX are more effective Other agents Bruce Kirkham @RheumNow #Rnl2022 https://t.co/rgdylgYDSb
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
RheumNow Podcast square

Consequences of TNF inhibition (3.18.2022)

d Jack Cush, MD

This week we're going to talk about the downside of TNF inhibitors, a few interesting observations in gout, and yes, kids do get COVID. We're also going to preview what's coming in April (hint: it's about PsA). This and more as Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.